RT Journal Article
SR Electronic
T1 Maternal PrEP use in HIV-uninfected pregnant women in South Africa: Role of Stigma in PrEP initiation, retention and adherence
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.11.24.20237867
DO 10.1101/2020.11.24.20237867
A1 Moran, Alexander
A1 Mashele, Nyiko
A1 Mvududu, Rufaro
A1 Gorbach, Pamina
A1 Bekker, Linda-Gail
A1 Coates, Thomas J.
A1 Myer, Landon
A1 Davey, Dvora Joseph
YR 2020
UL http://medrxiv.org/content/early/2020/11/28/2020.11.24.20237867.abstract
AB Pregnant women in sub-Saharan Africa are at high risk of HIV acquisition and require effective methods to prevent HIV. In a cohort of pregnant women offered pre-exposure prophylaxis (PrEP), we evaluate the relationship between internalized and anticipated stigma and PrEP initiation at first antenatal visit, 3-month continuation and adherence using multivariable logistic regression. High internalized and anticipated PrEP stigma are associated with lower PrEP initiation at first antenatal visit (aOR internalized stigma=0.06; 95%CI=0.03-0.12 & aOR anticipated stigma=0.53; 95%CI=0.29-0.97) compared to women with low reported stigma, after controlling for covariates. Women whose partners have not been tested for HIV or whose serostatus remains unknown have 1.6-times odds of PrEP retention at 3-months compared to women whose partners have been tested (aOR=1.60; 95%CI=1.02-2.52) after adjusting for covariates. PrEP counseling and maternal PrEP interventions must consider individual- and relational-level interventions to overcome anticipated PrEP stigma and other barriers to PrEP initiation and adherence.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT03902418Funding StatementDJD received funding from Fogarty International Center and National Institute of Health (K01TW011187), TC and LM received funding from National Institute of Mental Health (R01MH116771). The authors have no conflicts of interest to declare that are relevant to the content of this article.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Human Research Ethics Committee at the University of Cape Town (#297/2018) and by the University of California, Los Angeles Institutional Review Board (IRB#18-001622).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesStudy data are stored securely per the approved protocol.